{"id":793134,"date":"2024-12-06T14:11:49","date_gmt":"2024-12-06T19:11:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/"},"modified":"2024-12-06T14:11:49","modified_gmt":"2024-12-06T19:11:49","slug":"wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/","title":{"rendered":"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Dec.  06, 2024  (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (\u201cApplied Therapeutics\u201d) common stock (NASDAQ: APLT).<\/p>\n<p align=\"justify\">Applied Therapeutics is a clinical-stage biopharmaceutical company. Applied Therapeutics\u2019 leading drug candidate is govorestat (AT-007), which is used to treat Galactosemia and Sorbitol Dehydrogenase Deficiency. Galactosemia is a devastating rare pediatric metabolic disease. On January 3, 2024, Applied Therapeutics announced it submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) in December 2023 for the treatment of Classic Galactosemia.<\/p>\n<p align=\"justify\">After the market closed on November 27, 2024, Applied Therapeutics announced the FDA had issued a Complete Response Letter for the NDA for govorestat. The press release stated \u201cthe FDA completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in the clinical application.\u201d On this news, Applied Therapeutics\u2019 stock price plummeted $6.54 per share to $2.03 on November 29, 2024, down 76.3% on extremely heavy volume.<\/p>\n<p align=\"justify\">After the market closed on December 2, 2024, Applied Therapeutics disclosed it received a Warning Letter from the FDA. On December 3, 2024, the FDA posted the Warning Letter on its website. The letter made it clear that Applied Therapeutics knew since at least May 2024 that the FDA had significant issues with the govorestat NDA.<\/p>\n<p align=\"justify\">Investors who lost over $25,000 trading in Applied Therapeutics common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com.<\/p>\n<p align=\"justify\">Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper\u2019s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm\u2019s website at www.wolfpopper.com.<\/p>\n<p align=\"justify\">Attorney Advertising: Prior Results Do Not Guarantee a Similar Outcome.<\/p>\n<p align=\"justify\">Wolf Popper LLP<br \/>Adam Savett<br \/>845 Third Avenue<br \/>New York, NY 10022<br \/>Tel.: (212) 451-9655<br \/>Email: asavett @wolfpopper.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDI5NzcxMTUtZmVjZi00YjNkLTk5NjctYWIzYjA5MjkzOGExLTEwMjkyMTk=\/tiny\/Wolf-Popper-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (\u201cApplied Therapeutics\u201d) common stock (NASDAQ: APLT). Applied Therapeutics is a clinical-stage biopharmaceutical company. Applied Therapeutics\u2019 leading drug candidate is govorestat (AT-007), which is used to treat Galactosemia and Sorbitol Dehydrogenase Deficiency. Galactosemia is a devastating rare pediatric metabolic disease. On January 3, 2024, Applied Therapeutics announced it submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) in December 2023 for the treatment of Classic Galactosemia. After the market closed on November 27, 2024, Applied Therapeutics announced the FDA had issued a Complete Response Letter for the NDA for govorestat. The press release stated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793134","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (\u201cApplied Therapeutics\u201d) common stock (NASDAQ: APLT). Applied Therapeutics is a clinical-stage biopharmaceutical company. Applied Therapeutics\u2019 leading drug candidate is govorestat (AT-007), which is used to treat Galactosemia and Sorbitol Dehydrogenase Deficiency. Galactosemia is a devastating rare pediatric metabolic disease. On January 3, 2024, Applied Therapeutics announced it submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) in December 2023 for the treatment of Classic Galactosemia. After the market closed on November 27, 2024, Applied Therapeutics announced the FDA had issued a Complete Response Letter for the NDA for govorestat. The press release stated &hellip; Continue reading &quot;Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-06T19:11:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors\",\"datePublished\":\"2024-12-06T19:11:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/\"},\"wordCount\":324,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/\",\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=\",\"datePublished\":\"2024-12-06T19:11:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/","og_locale":"en_US","og_type":"article","og_title":"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors - Market Newsdesk","og_description":"NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (\u201cApplied Therapeutics\u201d) common stock (NASDAQ: APLT). Applied Therapeutics is a clinical-stage biopharmaceutical company. Applied Therapeutics\u2019 leading drug candidate is govorestat (AT-007), which is used to treat Galactosemia and Sorbitol Dehydrogenase Deficiency. Galactosemia is a devastating rare pediatric metabolic disease. On January 3, 2024, Applied Therapeutics announced it submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) in December 2023 for the treatment of Classic Galactosemia. After the market closed on November 27, 2024, Applied Therapeutics announced the FDA had issued a Complete Response Letter for the NDA for govorestat. The press release stated &hellip; Continue reading \"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-06T19:11:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors","datePublished":"2024-12-06T19:11:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/"},"wordCount":324,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/","name":"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=","datePublished":"2024-12-06T19:11:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTU2MSM2NjI2ODU4IzIwMTc2NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-applied-therapeutics-inc-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793134"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793134\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}